11:30 AM SIGN-IN & LUNCH • 12:00 PM - 1:30 PM
BANDOL 2 (NEW WYNN SPACE)
CE: Diabetic Retinopathy and Macular Edema: Treatment and Management Updates
Diabetic retinopathy (DR) is a common microvascular complication affecting approximately 86% of patients with type 1 diabetes and 40% of patients with type 2 diabetes. Overall, nearly 25% of patients with diabetes and DR are at risk for progressing to diabetic macular edema (DME), characterized by edema and retinal thickening, and subsequent vision loss. Mitigating treatment options include nonpharmacologic therapies, such as laser photocoagulation; vitrectomy; and pharmacologic options, such as corticosteroids and vascular endothelial growth factor (VEGF) inhibitors. To improve clinical outcomes in patients with DME, pharmacists must consider severity of disease, patient compliance, and cost effectiveness of agents prior to selection of therapy. This activity will highlight several opportunities for specialty pharmacists to take active roles in counseling patients from the importance of managing their diabetes and other comorbidities contributing to DR and DME to inquiring about patients’ adherence to regularly scheduled eye exams.